✳flâneur — a map of the web's best reading

Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease | Current Atherosclerosis Reports

link.springer.com · 252 words · saved by 1 readers

Patients with non-alcoholic fatty liver disease (NAFLD), often considered as the hepatic manifestation of the metabolic syndrome, represent a population at high cardiovascular risk and frequently suffer from atherogenic dyslipidemia. This article reviews the pathogenic interrelationship between NAFLD and dyslipidemia, elucidates underlying pathophysiological mechanisms and focuses on management approaches for dyslipidemic patients with NAFLD. Atherogenic dyslipidemia in patients with NAFLD results from hepatic and peripheral insulin resistance along with associated alterations of hepatic glucose and lipoprotein metabolism, gut dysbiosis, and genetic factors. Since atherogenic dyslipidemia and NAFLD share a bi-directional relationship and are both major driving forces of atherosclerotic cardiovascular disease (ASCVD) development, early detection and adequate treatment are warranted. Thus, integrative screening and management programs are urgently needed. A stepwise approach for dyslipid

Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease Statin Drugs (R. Ceska, Section Editor) Open access Published: 04 May 2022 Volume 24 , pages 533–546 ( 2022 ) Cite this article You have full access to this open access article Download PDF Save article View saved research Current Atherosclerosis Reports Aims and scope Submit manuscript Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease Download PDF Abstract Purpose of Review Patients with non-alcoholic fatty liver disease (NAFLD), often considered as the hepatic manifestation of the metabo

Explore this link on the map →

related reading